CD276 and cancer: Sacituzumab govitecan led to the validation of TROP2 as a target in TNBC, and SN-38-based ADCs in clinical evaluation highlight the potential of new targets in cancer types that were poorly represented in the ADC landscape (HER3, CEACAM5, B7-H3 and GPR20).